Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Limor, Toledano"'
Autor:
Bethlehem Mengesha, Shani Zilberman-Itskovich, Marina Bondarenco, Limor Toledano, Dror Marchaim, Ilan Youngster, Yael Kachlon, Ronit Zaidenstein, Nathan Strul, Tsilia Lazarovitch
Publikováno v:
Future Microbiology. 14:1489-1495
Aim: Recent guidelines recommended removing metronidazole as a therapeutic option for Clostridioides difficile infections (CDI). However, superiority of vancomycin over metronidazole in mild CDI is not established and use of vancomycin might lead to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c31475236956f91c719d0b8a2ffbe1bc
https://doi.org/10.2217/fmb-2019-0157
https://doi.org/10.2217/fmb-2019-0157
Autor:
Shani, Zilberman-Itskovich, Ilan, Youngster, Tsilia, Lazarovitch, Marina, Bondarenco, Limor, Toledano, Yael, Kachlon, Bethlehem, Mengesha, Nathan, Strul, Ronit, Zaidenstein, Dror, Marchaim
Publikováno v:
Future microbiology. 14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::965e599373b6f995ba29bb525458fb14
https://pubmed.ncbi.nlm.nih.gov/31913060
https://pubmed.ncbi.nlm.nih.gov/31913060
Autor:
Ilan, Youngster, Tsillia, Lazarovitch, Marina, Bondorenco, Yael, Kachlon, Limor, Toledano, Bethlehem, Mengesha, Ronit, Zaidenstein, Chen, Daniel, Mor, Dadon, Dror, Marchaim
Publikováno v:
Harefuah. 157(5)
The epidemiology of Clostridium difficile infections (CDI) have evolved dramatically in the past decade. Vancomycin is the treatment of choice for moderate to severe CDI. However, controlled comparative data pertaining to mild CDI is lacking. Further
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f8cf65b9b590c077d5a95d6bd04cde84
https://pubmed.ncbi.nlm.nih.gov/29804335
https://pubmed.ncbi.nlm.nih.gov/29804335
Autor:
Marina Bondorenco, Dror Marchaim, Zipora Lazarovitch, Betlehem Mengesha, Ilan Youngster, Yael Kachlon, Limor Toledano
Publikováno v:
Open Forum Infectious Diseases
Background The epidemiology and clinical characteristics of Clostridium difficile infections (CDI) have evolved dramatically in the past decade. Vancomycin is the treatment of choice for moderate to severe CDI, with superior cure rates observed in co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b834b2e1aa7b341ad43aa63771b9ef2
https://doi.org/10.1093/ofid/ofx163.966
https://doi.org/10.1093/ofid/ofx163.966